Solifenacin Succinate Patent Expiration
Solifenacin Succinate was first introduced by Astellas Pharma Us Inc
Solifenacin Succinate Patents
Given below is the list of patents protecting Solifenacin Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vesicare Ls | US9918970 | Pharmaceutical composition comprising solifenacin | May 18, 2031 | Astellas |
| Vesicare |
US6017927 (Pediatric) | Quinuclidine derivatives and medicinal composition thereof |
May 19, 2019
(Expired) | Astellas |
| Vesicare | US6017927 | Quinuclidine derivatives and medicinal composition thereof |
Nov 19, 2018
(Expired) | Astellas |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Solifenacin Succinate's patents.
Latest Legal Activities on Solifenacin Succinate's Patents
Given below is the list recent legal activities going on the following patents of Solifenacin Succinate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Sep, 2021 | US9918970 |
| Recordation of Patent Grant Mailed Critical
| 20 Mar, 2018 | US9918970 |
| Patent Issue Date Used in PTA Calculation Critical
| 20 Mar, 2018 | US9918970 |
| Mail Pre-Exam Notice | 01 Mar, 2018 | US9918970 |
| Email Notification Critical
| 01 Mar, 2018 | US9918970 |
| Electronic Review Critical
| 01 Mar, 2018 | US9918970 |
| Issue Notification Mailed Critical
| 28 Feb, 2018 | US9918970 |
| Dispatch to FDC | 26 Jan, 2018 | US9918970 |
| Reverse Issue Fee | 19 Jan, 2018 | US9918970 |
| Issue Fee Payment Verified Critical
| 18 Jan, 2018 | US9918970 |
Solifenacin Succinate's Family Patents
